Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults \>/= 18 years old
Histologically or cytologically confirmed advanced solid tumors that are refractory to standard therapy or for which no standard therapy exists (Monotherapy and in Cohorts A and B)
At least one lesion measurable by RECIST not previously irradiated (Monotherapy and in Cohorts A and B)
Histologically confirmed DLBCL(Cohort C)
Adequate organ and marrow function
ECOG performance status of 0 or 1
Willingness to provide consent for biopsy samples
You may not be if
Prior exposure to immunotherapy (either as a single agent or in combination) including but not limited to CD137 or OX40 agonists, anti-CTLA-4, anti-PD-1, or anti-PD-L1, anti-PD-L2 antibody or pathway-targeting agents
History of organ transplant that requires use of immunosuppressives
History of primary immunodeficiency or tuberculosis
Active or prior documented autoimmune disease within the past 3 years
Active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months
Major surgical procedure within 30 days prior to the first dose of investigational product or still recovering from prior surgery
Women who are pregnant or lactating
Clareo Health | A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
